EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Awakn Life Sciences's enterprise value is $4.15 Mil.
Awakn Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Oct. 2023 was $-6.26 Mil. Therefore, Awakn Life Sciences's EV-to-EBITDA for today is -0.66.
The historical rank and industry rank for Awakn Life Sciences's EV-to-EBITDA or its related term are showing as below:
AWKNF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -5.77 Med: -0.98 Max: -0.15
Current: -0.66
During the past 3 years, the highest EV-to-EBITDA of Awakn Life Sciences was -0.15. The lowest was -5.77. And the median was -0.98.
AWKNF's EV-to-EBITDA is ranked worse than 100% of 474
companies
in the Biotechnology industry
Industry Median: 9.165
vs AWKNF: -0.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-24), Awakn Life Sciences's stock price is $0.13736.
Awakn Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 was $-0.179. Therefore, Awakn Life Sciences's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Awakn Life Sciences EV-to-EBITDA Historical Data
The historical data trend for Awakn Life Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Awakn Life Sciences's EV-to-EBITDA
For the Biotechnology subindustry, Awakn Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Awakn Life Sciences's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Awakn Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Awakn Life Sciences's EV-to-EBITDA falls into.
Awakn Life Sciences EV-to-EBITDA Calculation
Awakn Life Sciences's EV-to-EBITDA for today is calculated as:
Awakn Life Sciences's current Enterprise Value is $4.15 Mil.
Awakn Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Awakn Life Sciences (OTCPK:AWKNF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Awakn Life Sciences's PE Ratio for today is calculated as:
Awakn Life Sciences's share price for today is $0.13736.
Awakn Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.179.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Awakn Life Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Awakn Life Sciences (Awakn Life Sciences) Business Description
Awakn Life Sciences Corp is a clinical-stage biotechnology company intended to develop therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder. The Company focuses on Alcohol Use Disorder (AUD), a condition affecting the people in the US and key international markets and many people globally for which the current standard of care is inadequate, enabling to provide breakthrough therapeutics to addiction sufferers in desperate need.
Awakn Life Sciences (Awakn Life Sciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AWKNF has been successfully added to your 